Purchase Order 36C24226P0344
Award Date 1/30/26
Potential Completion Date 3/1/26
Potential Value $39K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Northport, NY 11768, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Takeda Pharmaceuticals America Inc. was awarded a $36,984.28 firm fixed-price delivery order for TAKHZYRO 150 MG, a specialized pharmaceutical treatment for hereditary angioedema. The contract, issued on October 16, 2025, with an ultimate completion date of October 17, 2025, is a child order under Takeda's broader Blanket Purchase Agreement with the VA National Acquisition Center valued at $131.04 million. The award was issued without a set-aside designation, reflecting the specialized and...
- On January 15, 2026, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a delivery order valued at $38,097.52 to Takeda Pharmaceuticals America Inc. for TAKHZYRO 150 MG, a specialized pharmaceutical product used to treat rare genetic disorders. This firm fixed-price delivery order, with an ultimate completion date of January 20, 2026, represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and does not utilize a set-aside...
- This delivery order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9 awards Takeda Pharmaceuticals America Inc. a $36,890.40 firm fixed price contract to supply TAKHZYRO 150MG/ML SYRINGE 2ML PER SYRINGE with a quantity of 2. The contract is issued against Takeda Pharmaceuticals America Inc.'s existing Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB), with performance taking place in Lexington, Massachusetts. No...
- This federal contract award was issued by the Department of Veterans Affairs (VA) to Takeda Pharmaceuticals America Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited. The contract is a delivery order under Takeda's General Services Administration (GSA) Pharmaceuticals and Drugs Schedule contract, with a ceiling value of $55,335.60 and a completion date of June 28, 2024. The contract is for the supply of TAKHZYRO, a specialty pharmaceutical product...
- The Defense Logistics Agency awarded a $34,342.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Takhzyro 300 mg/2 ml syringes on April 25, 2025, with completion required by May 16, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively granted with no set-aside designation, and...
- The Department of Veterans Affairs (VA) Veterans Health Administration awarded a firm fixed-price delivery order to Takeda Pharmaceuticals America Inc. under the company's Pharmaceuticals and Drugs GSA Schedule contract. The $36,890.40 order is for the specialty pharmaceutical product TAKHZYRO 150MG ML SYRINGE 2ML PER SYRINGE, which is used to treat hereditary angioedema. The delivery order has an April 2024 completion date and will support patient care programs across the VA's Veterans...
- The Department of Veterans Affairs (VA) Veterans Health Administration awarded a delivery order contract to Takeda Pharmaceuticals America Inc., a subsidiary of Takeda Pharmaceutical Company LIMITED, for LANADELUMAB-FLYO 150MG/ML INJ, SYRINGE,2ML (TAKHZYRO). The $221,342.40 firm fixed-price contract is issued against Takeda's Pharmaceuticals and Drugs General Services Administration (GSA) Schedule. This specialized pharmaceutical product is used to treat hereditary angioedema, a rare and...
- This federal contract award is for the pharmaceutical product TAKHZYRO 150 MG, which was awarded to Takeda Pharmaceuticals America Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited. The contract, valued at $36,984.28, is a delivery order with a firm fixed-price pricing type, and the ultimate completion date is August 27, 2025. The contract was awarded by the Veterans Integrated Service Network 5, a civilian defense agency, and is part of the General...
- This federal contract award from the Defense Logistics Agency (DLA) was issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $32,448.80 firm fixed-price delivery order is for the supply of TAKHZYRO 300 MG/2 ML syringes, a specialty medication used for the treatment of hereditary angioedema. The award has an ultimate completion date of May 14, 2024 and was made on April 23, 2024. This delivery order is a part of Amerisourcebergen's...
- The Department of Veterans Affairs Veterans Health Administration awarded Takeda Pharmaceuticals America Inc. a $36,101.68 firm fixed price delivery order against the company's GSA Schedule contract for Pharmaceuticals and Drugs. The delivery order is for TAKHZYRO 150MG/ML SYRINGE 2ML SYRINGE (2) to be supplied to Veterans Integrated Service Network 9, with performance taking place in Lexington, Massachusetts from September 6-7, 2023. As the prime contractor, Takeda Pharmaceuticals America...